Vincent J. Angotti has bought stock on 5 days since Aug 2018

Vincent J. Angotti is the Chief Executive Officer and a director of Talphera, Inc. (TLPH), positions he has held since March 2017.( Aged 57, he brings over two decades of experience leading executive and commercial teams in public and private life sciences companies.( Prior to Talphera (formerly AcelRx Pharmaceuticals), he served as CEO of XenoPort, Inc., where he orchestrated the acquisition of Horizant from GSK, executed a successful rebranding and relaunch, culminating in XenoPort's $0.5 billion acquisition by Arbor Pharmaceuticals in 2016.(

Angotti holds a B.S. in Business Management from Cornell University and an MBA with honors from Columbia University.( He owns approximately 0.79% of Talphera's shares, valued at around $321,000, and his total compensation is about $1.04 million annually, comprising 64% salary and 36% bonuses/stock/options.( Recently, on February 12, 2026, he purchased 105,364 shares at $0.8123 each, along with 594,000 stock options, demonstrating confidence in the company amid its development-stage focus on products like Niyad for CRRT anticoagulation.(

Written by Perplexity from public sources.